Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting
cognition, function, and behavior. Alzheimer's disease progresses along a continuum from …

Alzheimer's disease (AD) is an irreversible brain disorder associated with slow, progressive
loss of brain functions mostly in older people. The disease processes start years before the …

Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly
worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the …

Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The
presence of extracellular β-amyloid deposition as neuritic plaques and intracellular …

Alzheimer's disease (AD) is an age‐associated neurodegenerative disorder with
multifactorial etiology, intersecting genetic and environmental risk factors, and a lack of …

Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with
cognitive decline. Memory problems are typically among the first signs of cognitive …